ECOG-ACRIN EA6174 (Merkel Cell Carcinoma) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn if we can lower the chance of your cancer growing back by adding the study drug (Pembrolizumab) after your surgery.
Stage I -IIIB Merkel Cell Carcinoma (MCC) that has been removed by surgery
Who Can Participate in the Study?
Adults with Merkel cell carcinoma (MCC).
What is Involved?
If you choose to join the study you will:
-Either get the study drug, Pembrolizumab, after surgery, OR
-Be observed after surgery for up to 1 year (no study drug)
-Complete regular follow-up appointments with your doctor every 6 months for 5 years